DRREDDY Ltd.

3062.05INR + 107.35 (+ 3.63%) VOLUME : 559798
    Average Volume
  • 5-Day 531,847.20
  • 20-Day 442,861.70
  • 3-Months 556,870.55

MARKET CLOSED

Price Table

Date Open High GREEN: if High is higher than last 2 days high
RED: if high is lower than last 2 days high
Low GREEN:if Low is higher than last 2 days low
RED: if low is lower than last 2 days low
LTP Close GREEN:if Day's Closing is near the Day's High
RED: if low is lower than last 2 days low
Volume Delivery % 20 Day SMA GREEN: if Day's Closing is above 20-Day SMA
RED: if Day's Closing is below 20-Day SMA
50 Day SMA GREEN: if Day's Closing is above 50-Day SMA
RED: if Day's Closing is below 50-Day SMA
100 Day SMA GREEN: if Day's Closing is above 100-Day SMA
RED: if Day's Closing is below 100-Day SMA
200 Day SMA GREEN: if Day's Closing is above 200-Day SMA
RED: if Day's Closing is below 200-Day SMA
22-Jan-20 3060.55 3105.05 3047.40 3062.05 3062.05 559,798 - - - - -
13-Jan-20 2932.90 2966.50 2915.70 2954.90 2954.70 441,864 36% 2,883.86 2,865.13 2,774.14 2,730.57
10-Jan-20 2930.00 3008.00 2925.15 2936.60 2933.00 1,127,147 24% 2,877.20 2,861.70 2,769.71 2,729.15
09-Jan-20 2911.60 2936.60 2901.00 2915.00 2920.50 375,496 36% 2,875.84 2,858.24 2,765.94 2,727.77
08-Jan-20 2875.00 2905.00 2866.00 2900.00 2897.25 279,023 38% 2,874.20 2,855.88 2,762.47 2,726.41
07-Jan-20 2890.00 2910.00 2871.05 2880.00 2884.20 357,635 34% 2,874.21 2,853.65 2,759.22 2,725.20
06-Jan-20 2871.00 2897.80 2854.20 2885.00 2878.85 357,737 52% 2,875.44 2,851.86 2,755.95 2,724.12
03-Jan-20 2864.90 2897.00 2852.05 2887.00 2883.90 344,678 29% 2,876.04 2,850.79 2,752.72 2,722.85

Performance

Key Data

Day High Low Range

Time Lowest Highest
10 AM 3048.05 3105.05
11 AM 3048.05 3105.05
12 PM 3048.05 3105.05
1 PM 3048.05 3105.05
2 PM 3048.05 3105.05

Company Profile - DRREDDY Ltd.

Dr. Reddys Laboratories Limited or DRREDDY

It is a 25–year old company catering to the needs of the pharmaceutical sector, and it began its operation in 1984 in the Active Pharmaceutical Ingredients (API) section. It started with a single drug in a 60-ton facility near Hyderabad and also shipped its first consignment of the Methyldopa drug towards West Germany in 1986. The Company is among the top three API players worldwide. Also, it is a global pharmaceutical company, which has its headquarters in India. It also has a global presence in 100+ countries, with its subsidiaries in the countries such as the UK, US, Germany, Russia, and Brazil. And joint ventures in Australia, China, and South Africa. And representative offices in 16 countries and third–party distribution setups in about 21 countries. It is also the first pharmaceutical company in Asia, outside Japan, which is listed on the NYSE and largest player in the custom pharmaceutical services o ... r CPS business in India. It has launched brands such as Nise, Ciprolet, Enam, Stamlo, Omez, and Ketorol, and many others. The Company also launched Imitrex (sumatriptan succinate) tablets in several dosages of 25mg, 50mg, and 100mg in the US. Also, it is the authorized generic version of the GlaxoSmithKline’s Imitrex. It is the first company to launch Imitrex (with its generic version) in the US market. Such tablets are for the treatment of migraine in adults.

The Company includes:

  • 6 FDA–inspected plants in INDIA.
  • 1 Cytotoxic facility.
  • 1 FDA–inspected plant in Mexico.
  • 1 FDA–inspected plant in Mirfield, UK.
  • 3 Technology development centers (2 in Hyderabad, INDIA; 1 in Cambridge, UK).

Some of the Milestones:

  • In June 2009, Dr. Reddy's announces a strategic alliance with GSK for the development and marketing of the selected products in emerging markets overseas.
  • In October 2010, Dr. Reddy's Laboratories and SoluBest, an Israel–based clinical-stage developer, closed a collaboration contract for developing a new, exclusive formulation of one of the latter’s pipelines compounds.
  • In October 2010, Dr. Reddy’s Laboratories inked a licensing pact with Cipla for exclusive marketing rights of a portfolio of OTC and prescription products in both Russian and Ukraine markets.
  • In November 2010, GlaxoSmithKline and Dr. Reddy's agreed to the sale of the US Penicillin Facility and Products. In this, GSK decided to transfer ownership of its penicillin manufacturing sites in Bristol, US, and rights for the Augmentin and Amoxil brands in the US to Dr.Reddy’s Laboratories.
  • In December 2010, the company entered an agreement with R–Pharma of Russia in the sector of high–technology and knowledge sharing.
  • In January 2011, the company entered into a pact with UK–based contract research firm, Argenta, for the collaboration in drug discovery. According to this pact, the duo will work in the sector of pain and inflammation.
  • In March 2011, the company completed the acquisition of GlaxoSmithKline’s (GSK) United States oral penicillin facility and product portfolio under the agreement signed and announced by the companies in November 2010.
  • In September 2011, the company came into a settlement agreement with Pfizer, to resolve litigation associated with Lipitor(R) Tablets, known generically as Atorvastatin Calcium tablets.
  • In 2011:
  • The Company launches Levocetirizine tablets in the US.
  • The Company launches a generic allergy drug in the US.
  • The Company launches pegfilgrastim in India under the brand name 'Peg–grafeel.
  • In 2012:
  • The Company launches Quetiapine Fumarate Tablets.

Some of the Businesses:

  • Pharma Services and API business
Under this segment, the company offers over 100 molecules to customers across the world. APIs are its core strength, having a wide spectrum of portfolios. It submits the most vital number of US DMF from India. It entered into the custom pharmaceutical services (CPS) in 2001. Along with this acquisition of Roche’s API manufacturing unit Mexico in 2005, the company got a boost in the CPS business. It also acquired the small molecule business of Dow Pharma at its Mirfield and Cambridge sites, the UK in 2008, also strengthening its CPS business.
  • Generics Medicines:
Under this segment, the Company manufactures generic medicines with the business that is spread across India, Russia, the US, and Germany. It is in the top ten players in India.
  • Proprietary Products:
Under this segment, it includes NCE research, biologics business, and many differentiated formulations conducted in the US. Also, it launched Grafeel (Filgrastim) and Reditux (Rituximab). Some of the Achievements:
  • The Company was ranked among the top ten in ‘The Best Companies to Work for in India’ survey conducted in collaboration by TNS India, Business Today, and Mercer Human Resource Consulting.
  • The Company also received the Recruitment and Staffing Best in Class or RASBIC Award for the ‘Best Use of Technology for Recruiting’ at the Asia Pacific HRM Congress.
  • The Company also received the Certificate of Merit for Innovative Training Practices among Indian organization by ISTD or Indian Society for Training and Development.
  • The Company received the NHRD Inspire award in 2011 for Learning & Development for organization best practices in the sector of competency framework in the Non–IT sector.